Search results for " mof"

showing 10 items of 19 documents

Structure effects induced by high mechanical compaction of STAM-17-OEt MOF powders

2021

Financial support by PJ-RIC-FFABR_2017 and the EPSRC grant EPSRC industrial CASE award (grant EP/N50936X/1) are acknowledged. The research programme Nanoporous materials (P1-0021) financially supported by Slovenian Research Agency (ARRS) is acknowledged as well. Metal-organic frameworks (MOFs) are promising materials for many potential applications, spacing from gas storage to catalysis. However, the powder form of which they are generally made is not suitable, mainly because of the low packing density. Powder compaction is therefore necessary, but also challenging because of their typical mechanical fragility. Indeed, generally, they undergo irreversibly damages upon densification processe…

010405 organic chemistryChemistryNanoporousCompactionNanotechnologyFlexible MOFs3rd-DASMetal-organic frameworks010402 general chemistryMOF stabilityQD Chemistry01 natural sciencesMOF tableting0104 chemical sciencesInorganic ChemistryQDMOF TabletingEPR spectroscopy
researchProduct

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

2009

We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …

AdultMalemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentCalcineurin InhibitorsUrologyRENAL DYSFUNCTIONRenal functionCALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MYCOPHENOLATE MOFETIL; RENAL DYSFUNCTIONLiver transplantationKidney Function TestsTacrolimusMycophenolic acidNephrotoxicitychemistry.chemical_compoundmedicineHumansMYCOPHENOLATE MOFETILAgedTransplantationCreatinineIMMUNOSUPPRESSIONDose-Response Relationship Drugbusiness.industryGraft SurvivalMiddle AgedMycophenolic AcidTacrolimusLiver TransplantationCalcineurinliver transplantTreatment OutcomechemistryCreatinineImmunologyKidney Failure ChronicDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsGlomerular Filtration Ratemedicine.drug
researchProduct

Modeled Catalytic Properties of MOF-Based Compounds” in “Metal-Organic Frameworks: Materials Modeling Towards Potential Engineering Applications

2015

Catalysis MOF Materials Modelling DFT
researchProduct

Conversion of levulinic acid to γ-valerolactone over Zr-containing metal-organic frameworks: Evidencing the role of Lewis and Brønsted acid sites

2021

Zr-containing UiO-66 and MOF-808 are evaluated for converting levulinic acid (LA) into γ-valerolactone (GVL) through various routes: (i) Step-wise esterification of LA to n-butyl levulinate (nBuL) and Meerwein-Ponndorf-Verley (MPV) reduction to GVL; (ii) One-pot two-steps esterification with n-butanol followed by MPV reduction with sec-butanol; and (iii) direct conversion of LA into GVL through a tandem reaction. Selection of this multistep complex reaction evidences the participation of the different acid sites (Lewis or Brønsted) of the material in each individual step: Brønsted-induced acid sites catalyze esterification reaction efficiently, while Lewis acid sites are the preferred sites…

ChemistryProcess Chemistry and TechnologyZirconium MOFsCatalysisCatalysischemistry.chemical_compoundSulfationLevulinic acidCascade reactionUiO-66Levulinic acidOrganic chemistryMetal-organic frameworkLewis acids and basesPhysical and Theoretical ChemistrySulfateGamma-valerolactoneBrønsted–Lowry acid–base theoryMOF-808Molecular Catalysis
researchProduct

Metal–Organic Frameworks (MOFs) Containing Adsorbents for Carbon Capture

2022

This research was funded by the European Regional Development Fund project “Innovation of the waste‐to‐energy concept for the low carbon economy: development of novel carbon capture technology for thermochemical processing of municipal solid waste (carbon capture and storage from waste—CCSW)”, grant number 1.1.1.1/19/A/013.

Control and OptimizationCuBTCRenewable Energy Sustainability and the EnvironmentMOF-compositescarbon captureUiO-66-BTECEnergy Engineering and Power Technologymontmorilloniteanalytical characterizationUTSA-16:NATURAL SCIENCES [Research Subject Categories]desorptionbiocharElectrical and Electronic EngineeringEngineering (miscellaneous)MOF; carbon capture; MOF-composites; montmorillonite; biochar; CuBTC; UTSA-16; UiO-66-BTEC; analytical characterization; desorptionEnergy (miscellaneous)MOFEnergies
researchProduct

Structure solution of zeolites by automated electron diffraction tomography - Impact and treatment of preferential orientation

2014

Abstract In this paper the reliability of structure solution of nano-crystalline porous compounds with preferred orientation based on automated electron diffraction tomography (ADT) is discussed. It will be shown that the limitations of the data acquisition geometry can be overcome by completing the missing diffraction data with additional diffraction information. Apart from different ways of sample preparation, data merging with either additional ADT data sets or intensities derived from X-ray powder diffraction comprise an effective way to improve the accuracy of the structure solution.

DiffractionZeoliteOrientation (computer vision)ChemistryGeneral ChemistryCondensed Matter PhysicsElectron diffraction; MOF; Structure determination; ZeoliteComputational physicsCrystallographyData acquisitionElectron diffractionElectron diffractionMechanics of MaterialsGeneral Materials ScienceSample preparationTomographyStructure determinationPowder diffractionElectron backscatter diffractionMOF
researchProduct

Applications of automated diffraction tomography (ADT) on nanocrystalline porous materials

2013

Abstract Many porous materials, both inorganic and hybrid organic–inorganic, can only be synthesized as nanocrystals. X-ray powder diffraction delivers one-dimensional data from the overall sample and is therefore often limited by peak overlap at low or medium resolution and by peak broadening. Thus, structure solution of materials with large unit cells and low symmetry, disorder or pseudosymmetry, or available only in polyphasic systems, turns out to be problematic or even impossible. Electron diffraction allows collecting three-dimensional structure information from nanocrystalline materials, but is traditionally biased by low completeness of the diffraction data, dynamical scattering and…

DiffractionZeoliteReflection high-energy electron diffractionChemistrybusiness.industryGeneral ChemistryElectron diffraction; MOF; Structure determination; ZeoliteCondensed Matter PhysicsNanocrystalline materialDiffraction tomographyElectron diffractionOpticsElectron diffractionMechanics of MaterialsGeneral Materials SciencePorous mediumbusinessStructure determinationPowder diffractionMOFElectron backscatter diffraction
researchProduct

Effectiveness of cyclosporine and mycophenolate mofetil in a child with refractory evans syndrome

2011

Evans Syndrome is a rare autoimmune disease consisting of hemolytic anemia, thrombocytopenia and/or neutropenia. It may be associated with other autoimmune or lymphoproliferative diseases. Its course can be extremely serious and, rarely, even life-threatening

Hemolytic anemiaVincristinePediatricsmedicine.medical_specialtyEvans syndromeoutcome.CyclophosphamideEvans’ syndrome Cyclosporine Mycophenolate mofetil Treatment Outcomelcsh:MedicineCase ReportNeutropeniaPediatricshemic and lymphatic diseasesmedicineevans syndromeOutcomeAutoimmune diseasebusiness.industryMycophenolate mofetillcsh:Rlcsh:RJ1-570lcsh:PediatricsEvans’ syndromemedicine.diseaseDiscontinuationTreatmentImmunologyCyclosporineRituximabbusinessmedicine.drugPediatric Reports
researchProduct

Influence of thermally induced structural transformations on the magnetic and luminescence properties of tartrate-based chiral lanthanide organic-fra…

2020

This work reports on the synthesis and characterization of five enantiomeric pairs of isostructural 3D metal-organic frameworks (MOFs) with the general formula {[Ln2(μ4-tar)2(μ-tar)(H2O)2]·xH2O}n [where Ln(iii) = Tb (Tb-L and Tb-D), Dy (Dy-L and Dy-D), Ho (Ho-L and Ho-D), Er (Er-L and Er-D) and Tm (Tm-L and Tm-D); tar = tartrate (d- or l-) and x = 3 or 4 depending on the counterpart], which possess interesting luminescence and magnetic properties. These MOFs undergo progressive and reversible dehydration processes upon controlled heating yielding three crystalline phases (Ln-L′, Ln-L′′ and Ln-L′′′). Alternating current magnetic measurements on Tb, Dy and Er-based compounds exhibit field ind…

LanthanideMaterials sciencePhotoluminescencelanthanide organic-frameworks MOF chiral circular dichroismGeneral ChemistryTartrateCrystallographychemistry.chemical_compoundchemistrySettore CHIM/03 - Chimica Generale E InorganicaMagnetMaterials ChemistryMoleculeIsostructuralEnantiomerLuminescenceJournal of Materials Chemistry C
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct